Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is the
reason behind the transmission of the recently prevailing disease worldwide and is
known as coronavirus disease 19 (COVID-19). Coronavirus was first diagnosed in
Wuhan, China 2019, which followed a worldwide spread. Whereas assays associated
with the examination of virus molecules only detect the hereditary viral substance in
the patient's body. On the other hand, the novel coronavirus requires the diagnosis of
high serological parameters to examine specific antibodies of SARS-CoV-2. In this
case, the only solution is the -linked immunosorbent assay (ELISA) test based on
hunting the antigens. In this technique, the combination of antibodies is derived from
the S proteins present in the cells of infected coronavirus patients. By applying these
test assays for the COVID-19 patients, it is obvious that the nature of the testing is
specific and sensitive. This test allows the detection of serum through seroconverts
since the visible emergence of symptoms of SARS-CoV-2 in patients. The major
benefit of this method is that it takes less time during the examination. Instead, it deals
with the identifications of different antigens found in the human body. These tests play
a pivotal role in characterizing introduction and recognize profoundly receptive human
donors. Herein, we developed an ELISA assay for the easy detection of SARS-CoV-2
and nucleocapsid protein expression levels as an early tool for this disease.
Keywords: ELISA, Molecular detection, Nucleocapsid protein, RT-PCR, SARSCoV-
2.